SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending amid a mixed sentiment, with some traders pointing to a recent report highlighting security flaws in its battlefield communication system while others dismiss it as a hit piece designed to create a buying opportunity. The community is actively debating the company's valuation and future growth prospects in the AI space, with some calling it overvalued and others believing it has significant long-term potential. Despite the debate, some are taking advantage of the dip and loading up on shares, anticipating a rebound.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending after announcing a partnership with Perplexity AI to enhance content discovery and bundle services, sparking community excitement about AI integration. Discussions also revolve around Rumble's ties to cryptocurrency through Tether and potential benefits from a Trump administration. Some traders are eyeing a potential short squeeze given the high short interest.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid excitement over the company's shift to quantum computing for cryptocurrency applications, particularly its partnership related to LightSolver's laser-based processing units. The community is actively discussing the potential for energy savings and comparing it to other trending quantum stocks. Some traders are closely watching its threshold list status and awaiting news of potential contracts.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its potential as a culture coin and a symbol of freedom within the digital currency space. The project is drawing attention for its association with the cannabis culture and its aim to provide a decentralized financial tool. Community is also celebrating the 420k BURN event with a livestream, calling it a significant step for the project.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending due to Citron Research's positive outlook, sparking significant trading volume and community discussion about a potential short squeeze. Community members are debating the company's long-term prospects, comparing it to other telehealth plays, and speculating on factors such as potential acquisitions and partnerships. Overall, the conversation centers on whether Teladoc is undervalued and poised for a breakout.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending as traders discuss its potential for a squeeze, with some anticipating a rise to $10 or even $20. This speculation follows news of FDA Fast Track designation for ALTO-101 and investors are actively monitoring chat rooms, hoping for a breakout. The community also discusses the company's financials, pipeline and potential readouts.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is trending due to discussions surrounding potential White House talks and government funding related to rare earth minerals. Community members are speculating on a potential deal with the Trump administration to boost domestic supply and reduce reliance on China. Some traders are noting the stock's breakout, short interest, and sector momentum, while others remain skeptical.

Astrotech Corp. engages in the mass spectrometry company that launches, manages and commercializes scalable companies based on its innovative core technology through its wholly-owned subsidiaries. Its business units include 1st Detect, BreathTech, and AgLab. The company was founded in 1984 and is headquartered in Austin, TX.

Astrotech Corp

ASTC is experiencing increased volume and momentum, leading to community speculation about a potential breakout and larger move. Some traders are attributing the increased interest to the company's expansion of operations. Others suggest possible confusion with AST SpaceMobile (ASTS) as a catalyst for the current trading activity.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent surge in quantum computing stocks, fueled by a $5.7 million sale of two quantum computers. Community discussions revolve around the stock's high valuation and potential for a short squeeze, with bullish investors targeting higher prices while bears anticipate a significant correction. The broader context involves the rapidly growing quantum computing sector and its speculative nature.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending as investors discuss its potential role in solving AI's energy consumption challenges, with some viewing it as a more energy-efficient alternative to classical computers. The community is actively debating the company's valuation and long-term prospects in the burgeoning quantum computing sector, especially when compared to its peers. Positive analyst coverage and potential big tech partnerships are also fueling the bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently&nbsp;announced product launches of <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=m_DdCQTpOIEkyMW6a_LTNu80nA-fvUjxL3WRLmnGS69pjlEjzE7uri5nWw8o-jN5ufZ7dm_TD-F_EgPyk3wUaQdHmXCqk3fv6wOqrJUixIc=">Healthy Extracts, Inc.</a>(“Healthy Extracts,” OTCQB: HYEX), whose products apply Gelteq’s proprietary gel technology, <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=jVTfFSVxnjolcQWdJUHguUDpIFQsKOiqOBXBpcPqudxVaqM7qCSY6qp7CcK5vPQJFCo7hIArwK5VrglasVoSV6fkl1MhXuC0Z8-hE_a4204rIsukKFHSs6N8s2fDFE3nNeNsvZBeBaVYTKiPqDW3LCAe7Pbvi1Ykp2jwWuGNhVBrcGVtaGDqvv_XCRaSX9V2pmGKXGiBfHNkQZ7JeBNpdl8KBByCsg5_bPZoMX49Lldu2oACh7Wdw4rKa5E1y6JJfaWZzk6107bQ3c5yeCotSV3KY6uN9ysKWvWsic3iFkfv13xMn1h_G_ovXuIFktP5">into the U.S. nutraceutical market</a>.The Healthy Extracts products are the first to reach Gelteq’s U.S. warehousing facility using Gelteq’s delivery platform, an important milestone that marks Gelteq’s transition from R&amp;D to active commercialization in the U.S. This development highlights both the growth potential of Gelteq’s technology in large-scale wellness markets in the U.S. and its ability to meet consumer demand for innovative, convenient, and clinically-informed formats.“We are pleased to see Gelteq’s technology expand into the U.S. market through our collaboration with Healthy Extracts,” said Nathan Givoni, CEO of Gelteq. “Healthy Extract’s launch demonstrates how our gels can be adapted to create differentiated, consumer-friendly solutions, while paving the way for additional products and partnerships across the U.S. market.”The collaboration with Healthy Extracts, first announced earlier this year, began with warehousing and fulfilment arrangements which laid the foundation for Gelteq's entry into the U.S. market. With this launch, the partnership with Healthy Extract has advanced into active sales and distribution, underscoring the growing momentum behind Gelteq’s gel delivery system and the potential for additional partnership opportunities in the U.S.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=CzDiesrgFr3dtr9zZyTAj8WQwqMRYCl9wExZjU5Avfu8KSGuGlzGWsggV7F94VXP7gCRfpAAoHjXJ2X5fMFejCkzv8bsd_YZymXULDOahWLGd0vI2gPkcqhcg17_0Yfr">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner

Gelteq has entered the U.S. market and transitioned from research and development to commercialization with the launch of gel-based products by its partner, Healthy Extracts.

Others

MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence study in September 2025 to evaluate its novel gel-based formulation of a widely used antihistamine for allergy treatment. The study will be conducted by Adgyl Lifesciences (a partner of Eurofins Advinus), a leader in preclinical contract research services.If preclinical results are successful, Gelteq anticipates advancing to human clinical trials targeting U.S. Food and Drug Administration (FDA) approval via the 505(b)(2) regulatory pathway.“Our gel-based delivery platform is expected to transform traditional pharmaceutical products currently available on the market, especially where patient compliance and dosage control are critical,” said Nathan Givoni, CEO of Gelteq. “By applying our technology to a well-established antihistamine, we see a significant opportunity to capture value in the allergy market, where patient-friendly formats and flexible dosing remain unmet needs.”Allergic conditions affect over 50 million people annually in the United States alone (1). The global antihistamine market was valued at approximately USD $9 billion in 2023 growing at a 6% CAGR, projected to reach over USD $12 billion by 2028 (2). Demand spans paediatric, adult, and increasingly, animal health (3), reflecting the diverse applications for antihistamine therapies.Gelteq’s proprietary gel formulations aim to address key limitations of traditional tablets and syrups, including palatability challenges for children, swallowing difficulties for elderly patients, and precise dosing needs in veterinary medicine (3).“Our innovative gel technology offers potential advantages in taste masking, ease of administration, and flexible dosing,” added Mr. Givoni. “These attributes are particularly relevant in paediatrics and veterinary care where delivering effective allergy treatments can be challenging.”About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=O19-A9YeYzwuzvF6uGAfqtDG5RRZjNh8mE7N1rM43qWuYEEherjJSFHi9Ncl812p3GbOQCQNBsWSS797RiLzww==">www.gelteq.com</a>.Gelteq Contact:Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 15, 2024. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.References<ol style="list-style-type:decimal;"><li>American College of Allergy, Asthma &amp; Immunology. (2023). Allergy facts. American College of Allergy, Asthma &amp; Immunology. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2GA_gxthxCKK2am7PO7NqJTQcy2YC8ka5Kcte6IYk-_rkMMxzQMPvg2HqpjhYc9h72dvj8f127hx_V37sDA6KM=">https://acaai.org/allergies/</a></li><li>Grand View Research. (2024, March). Antihistamine market size, share &amp; trends analysis report. Grand View Research. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH8PA2iF4YPFOJnnXWrzLVPWX86_Wv7NSRcESK7JjTDN70jZpuPqpdsx_TBhsE_ulMsIgBJxpUBj13R4ETgeMYf2vk4jcPQISkwfsg1zYJE63DSmPuNhJhhBdTdUIzZKfJ9KWwDWruOryJwg7nm8RSHcuoR3YA-Wn6p7-YvPDoF3fCQ0atmiqwvReNLCbM7tPS-i_fie6yjzGM21gSt4TLW8X8McYSh-w8FfqP1mvol0z">https://www.grandviewresearch.com/industry-analysis/antihistamine-market</a></li><li>MarketsandMarkets. (2023, November). Veterinary dermatology drugs market by product, animal type, route of administration, end user – Global forecast to 2028. MarketsandMarkets. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2Y1c895h1WrE2q8doDlYL1Ih6-5ysKO0PaJX-tphZJJStCjpjTLUUpMpUV9mhXVNK5FNLLa-zQHGWQ_B54syEdWd1IfeFXhWlqU7sjNYhquPgonhJoiVzv-ITdIV85I8IM23Z11Bfhxpq1a1_GLzd4eL402y-zBojIsxjwBqtdEDB_GkSWA1jEq6FQ_hAJ20teMk3pmiCXapAHCSC97v8t-RGifPW7uovJqJo2C_PfBuJyCntgc2WPWifTl4gP1FwrDiGwagc9NPUwLVWidNu47-s8qC0JOu9g0EzXQHXrvMq8x9Bg8Kt0gb5gX1HJARQ==">https://www.marketsandmarkets.com/Market-Reports/veterinary-dermatology-drugs-market-177021512.html</a></li></ol>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Study to Support Potential FDA Approval via 505(b)(2) Pathway

Jul. 17, 2025 8:30 AM ET<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#source=section%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AGELS">Gelteq Limited (GELS)</a>GlobeNewswireNEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link">GELS</a>) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to support the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets.IDT is internationally recognized for its expertise in pharmaceutical projects and contract manufacturing services developed across more than 50 years of operation and over 60 market-based drugs. The company specializes in pharmaceutical product development and cGMP manufacture including high containment, high potency manufacture of Active Pharmaceutical Ingredients (API), oral and sterile dose FDA and TGA approved laboratory testing, and clinical packaging. IDT is also at the forefront of developing and manufacturing advanced therapies including mRNA and Antibody Drug Conjugates (ADCs).“Partnering with IDT to establish a locally-based, purpose-built manufacturing facility strategically positions Gelteq to accelerate and scale our products for the global nutraceutical, pharmaceutical and animal health markets,” said Nathan Givoni, CEO of Gelteq. “IDT not only brings proven development, manufacturing and regulatory expertise to support our goals, but also a unique knowledge base to speed up the development of new products targeting these markets.”Paul McDonald, CEO of IDT Australia, commented: “We are excited to combine IDT’s proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.”Highlights of the Agreement:<ul><li>Facilities and Equipment required for the manufacture of Gelteq products, in a dedicated building and purpose-built facility, trained staff and operational support.</li><li>Compliance and Certification necessary for products in the therapeutic, veterinary and nutraceutical markets across various product presentations, including regulatory requirements, permits, and licenses from the APVMA, FDA, and TGA.</li><li>Rapid Scale Up Capability to integrate additional manufacturing space and equipment to support growth. &nbsp;</li></ul>About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition.The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=00K18qA_R_h14eUsBeqQWCgMgMmxuWb3BtGKz6ILL5yQ1_R8YgVe3aEx_L8wLAZZPAeltknTuVaIh-pb4Kiy8g==">www.gelteq.com</a> and our SportsGel brand website <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-p3-I0mUlJnWPMf-dUcDiLZEc5RjeyAm-S2zUBjuzZqsz6gVrldwGFhUq191BEReZ8bR_Byc31VTexJpTREpLHRAjbEauYCyxSObvUI2IKY=">www.sportsgel.com</a>.Gelteq Contact:&nbsp; Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=lXdnLIhrjHSBfmEF8ctV8ZAmFeM-Ds7RVQBML108A473uXIgHycUxnGOSxVLrfBanFWPU-bmwMn1gK9Fn6lO2U8ADzIpjoyqaUQJQBtbSJM=">mkreps@darrowir.com</a>Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.Source: Gelteq Limited 2025 GlobeNewswire, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities

https://seekingalpha.com/pr/20169476-gelteq-announces-agreement-with-idt-australia-to-secure-dedicated-new-product-development-and

Shares of Gelteq (GELS) soared 71% on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.gelteq.com/news-events/press-releases/detail/103/gelteq-expands-u-s-operations-with-healthy-extracts-inc">announced</a> an exclusive logistics and distribution agreement with Healthy Extracts Inc. in a bid to expand operations in North America.The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. Healthy Extracts is a publicly traded company focused on plant-based health supplements.Gelteq expects to rapidly scale the distribution of its white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and other products across the United States and Canada, while significantly reducing costs and boosting revenue potential.Under the new agreement, Healthy Extracts will manage all product receiving, secure warehousing, inventory, and order fulfillment from its Henderson, Nevada, facility. The collaboration is expected to reduce fulfillment costs and unlock high-margin revenue opportunities for both Gelteq and Healthy Extracts.“We believe this is a scalable, profitable model for both companies and our shareholders,” said Duke Pitts, President of Healthy Extracts.The initial products to be received under this new agreement are on track for market distribution by the third quarter (Q3) of 2025.On Stocktwits, retail sentiment around Gelteq jumped from ‘extremely bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_1_19_18_PM_png_58ec493774.webp" alt="GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GELS">GELS stock</a> is up by about 22% this year and down by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-fda-places-clinical-hold-on-gilead-trials-of-two-investigational-hiv-treatments/chl7qNLRbzY">US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes

The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner.

Equity

Gelteq Ltd. operates as a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.

Gelteq Ltd.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$1.28
Prev Close	$1.24
Open	$1.27
Dividend Yield	N/A
50-Day Moving Average	$1.46
Beta	1.37
Avg. Volume	3.69M
PE Ratio	N/A

52-Week High	$5.50
52-Week Low	$0.7701
Market Capitalization	$11.7M
EPS (Annual)	N/A
Price to Book	1.48
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

GELS
Gelteq Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest GELS News

GELS Gelteq Ltd.